CT Air-trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients (BenraliScan)
Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients
Sponsor: AstraZeneca
Listed as NCT03976310, this NA trial focuses on Asthma and remains completed. Sponsored by AstraZeneca, it has been updated 10 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Aug 2023 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2022 — Aug 2023 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2022 — Sep 2022 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Dec 2021 — Jan 2022 [monthly]
Recruiting NA
-
Jan 2021 — Dec 2021 [monthly]
Recruiting NA
-
Dec 2020 — Jan 2021 [monthly]
Recruiting NA
-
Jan 2020 — Dec 2020 [monthly]
Recruiting NA
-
Jul 2019 — Jan 2020 [monthly]
Recruiting NA
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- University Hospital, Montpellier
For direct contact, visit the study record on ClinicalTrials.gov .